TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05677360

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: HPV MISTICS -Provider Level
Description: The HPV MISTICS (Multilevel Intervention Strategies Targeting Immunization in Community Settings) provider-level intervention for all clinical staff (e.g., physicians, nurses, medical assistants) includes a 1-hour online training session on the Announcement Approach (i.e., presumptive recommendation) to recommend adolescent vaccinations.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: HPV MISTICS -Provider Level
Description: The HPV MISTICS (Multilevel Intervention Strategies Targeting Immunization in Community Settings) provider-level intervention for all clinical staff (e.g., physicians, nurses, medical assistants) includes a 1-hour online training session on the Announcement Approach (i.e., presumptive recommendation) to recommend adolescent vaccinations.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: HPV MISTICS - Parent Level
Description: The HPV MISTICS (Multilevel Intervention Strategies Targeting Immunization in Community Settings) parent-level intervention includes a low literacy pre-visit HPV vaccine notification post card in the parent's preferred language.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: HPV MISTICS - Parent Level
Description: The HPV MISTICS (Multilevel Intervention Strategies Targeting Immunization in Community Settings) parent-level intervention includes a low literacy pre-visit HPV vaccine notification post card in the parent's preferred language.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: HPV MISTICS- HPV Vaccine Champion Level
Description: The HPV MISTICS (Multilevel Intervention Strategies Targeting Immunization in Community Settings) system-level intervention involves training an HPV Vaccine Champion at each FQHC on the provider and parent EBIs to monitor and share clinic HPV initiation and completion rates with providers, and to implement reminder/recall systems for subsequent vaccine doses

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: HPV MISTICS- HPV Vaccine Champion Level
Description: The HPV MISTICS (Multilevel Intervention Strategies Targeting Immunization in Community Settings) system-level intervention involves training an HPV Vaccine Champion at each FQHC on the provider and parent EBIs to monitor and share clinic HPV initiation and completion rates with providers, and to implement reminder/recall systems for subsequent vaccine doses
Study: NCT05654142

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Base intervention
Description: 12 Group Lifestyle Balance videos and digital motivational messages

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Base intervention
Description: 12 Group Lifestyle Balance videos and digital motivational messages
Study: NCT04880109

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: APX-115
Description: Oral administration of APX-115 100 mg capsule once daily for 14 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral administration of placebo capsule once daily for 14 days
Study: NCT05654142

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Base intervention
Description: 12 Group Lifestyle Balance videos and digital motivational messages

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Augmented Intervention
Description: 12 Group Lifestyle Balance videos and digital motivational messages plus remote coaching for one-on-one and group-based problem-solving treatment via videoconference (preferred) or phone

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Augmented Intervention
Description: 12 Group Lifestyle Balance videos and digital motivational messages plus remote coaching for one-on-one and group-based problem-solving treatment via videoconference (preferred) or phone
Study: NCT05110690

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral Activation
Description: The behavioral intervention will consist of behavioral activation (BA), the basic premise of which is to help people with mental health problems to engage in activities that are reinforcing or meaningful and guided by their personal values

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Medication Optimization
Description: Medication optimization consists of a simple set of principles: reconcile patient's medications, identify the patient's likely need for, and interest in, a medication adjustment, make the adjustment, and assess the response to that adjustment.
Study: NCT05804370

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gleolan
Description: Gleolan is a prodrug that is metabolized intracellularly to form the fluorescent molecule Protoporphyrin IX (PpIX). The oral provision of Gleolan leads to a highly selective accumulation of PpIX in tumor cells. Following excitation with blue light (BL) (wavelength \[λ\] = 375 - 450 nm), the PpIX, which has accumulated selectively in tumor tissue, emits a red-violet light.
Study: NCT06554340

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Home-based aerobic training
Description: The aerobic training will focus on large, dynamic movements of the lower extremities using leg cycling ergometry on an upright cycle ergometer installed in the participant's homes and will progress in duration (10-40 minutes) and intensity (50-70% VO2 peak) over the 3-month intervention period. All participants will start exercise at 50% of VO2peak for 10-min as determined by the exercise test, for the first week, to individualize the exercise prescription. Progression will initially target duration with weekly progressions of 5 min to 30 min of exercise, followed by progression of intensity by 5% per week until 70% is attained, based on patient tolerance of the increased work.
Study: NCT04706299

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Resistance Exercise
Description: Participants will perform for each leg, 3 sets comprised of 15 repetitions set to 180 degrees per second of an isokinetic, concentric knee extension and flexion. Resulting in a 20 second long working set (10 seconds extension, 10 seconds flexion), per set. Each set will be followed by a 90 second period of recovery. After completing 3 sets on initial leg, testing will be set up for second leg.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Resistance Exercise
Description: Participants will perform for each leg, 3 sets comprised of 15 repetitions set to 180 degrees per second of an isokinetic, concentric knee extension and flexion. Resulting in a 20 second long working set (10 seconds extension, 10 seconds flexion), per set. Each set will be followed by a 90 second period of recovery. After completing 3 sets on initial leg, testing will be set up for second leg.
Study: NCT06172153

Intervention type: OTHER
Intervention: No interventions
Description: No intervention
Study: NCT05709301

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Donepezil Hydrochloride
Description: Donepezil 10mg once daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo
Study: NCT05189223

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief, values based intervention for early buprenorphine treatment
Description: The initial intervention structure consists of four weekly sessions. Session one focuses on values clarification using an empirically validated clinical exercise. The second session will include a discussion of the connection between values, addiction treatment engagement, and the challenges associated with discomfort (i.e., withdrawal and cravings) in early treatment. The third session will focus on barriers and goal setting to enhance self-efficacy for committed action. The final session will review progress made and focus on the Veterans' recovery plan moving forward. The initial study intervention will be refined iteratively using Phase 1 stakeholder and Phase 2 open trial participant feedback.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Brief, values based intervention for early buprenorphine treatment
Description: The initial intervention structure consists of four weekly sessions. Session one focuses on values clarification using an empirically validated clinical exercise. The second session will include a discussion of the connection between values, addiction treatment engagement, and the challenges associated with discomfort (i.e., withdrawal and cravings) in early treatment. The third session will focus on barriers and goal setting to enhance self-efficacy for committed action. The final session will review progress made and focus on the Veterans' recovery plan moving forward. The initial study intervention will be refined iteratively using Phase 1 stakeholder and Phase 2 open trial participant feedback.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as Usual
Description: Veterans will be recruited from an intensive treatment phase where all Veterans receive case management and regular group therapy in addition to appointments with their buprenorphine, methadone, or naltrexone prescriber. After the first two weeks, they have the option to continue with a less intensive group schedule and case management support through an Aftercare program.
Study: NCT05147571

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Responsive stimulation
Description: The RNS System provides closed loop responsive brain stimulation. The Neurostimulator monitors the electrical activity of the brain to detect abnormal activity that could lead to a seizure. If abnormal activity is detected, the neurostimulator delivers electrical stimulation to the brain through the leads to help prevent the seizure before it occurs.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham stimulation
Description: For those in the Sham Stimulation group, the RNS System will be set to detect abnormal activity but will not have responsive stimulation enabled. Both Sham and Active groups will undergo therapy testing at each appointment in order to maintain the blind.
Study: NCT06528847

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Benmelstobart
Description: The PD-L1 inhibitor Benmelstobart (TQB2450) is administered as an adjuvant therapy in patients with pathologic stage IB, IASLC grade 3 invasive lung adenocarcinoma who do not have EGFR active mutations or ALK rearrangement.
Study: NCT04218786

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Colchicine
Description: The tablet will be given once daily for the span of the study

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral tablet
Description: The tablet will be given once daily for the span of the study
Study: NCT05413239

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Psychoeducation to reduce diabetes distress and improve glycemic outcomes
Description: The intervention includes two types of sessions - those targeting an improvement in glycemic outcomes and those targeting a reduction in diabetes distress. Evidence indicates that psychoeducation and support are needed to improve self-care behaviors and optimize use of advanced diabetes technologies, which, in turn, can help improve diabetes control while also reducing diabetes distress. Participants will receive 4 one-on-one glycemic sessions and 8 one-on-one distress sessions, each lasting \~30 minutes. Sessions will be conducted in-person or remotely. The virtual sessions are intended to provide the extra psychoeducation and support needed for this high risk group without increasing the burden associated with frequent face-to-face sessions.
Study: NCT05504850

Intervention type: OTHER
Group type: OTHER
Intervention: Multicultural Health Diet
Description: The food-based components will be similar to the anti-inflammatory diet of the ongoing MHD study (NCT03240406), which emphasizes limiting animal and high saturated fat foods with focus on anti-inflammatory foods/food components specific to the cultural context of the participant. The diet will also be tailored to needs of the CKD population including a focus on lowering sodium intake. The intervention (dietary counseling) will be delivered by experienced kidney disease nutritionist.
Study: NCT05215275

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: exercise
Description: the exercise consists of two different modalities: moderate-intensity continuous training (MICT): the main MICT program will be designed to last 30 minutes. The MICT will be designed to involve core muscle training (e.g., march, step touch, lunge, V-step, box step, twist, knee up, scoop, and scissors).~high-intensity interval training (HIIT): The HIIT motions will be a mix of spiderman mountain climbers, standing oblique crunches, squats, froggers, jumping jacks, foot fire, jump squats, and mountain climbers. A total of four sets will be performed with 1-minute rests between sets. Each set comprises eight motions, with each motion lasting 30 seconds and a rest interval of 10 seconds between motions. Participants in the HIIT group will perform the most repetitions possible within 30 seconds.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: exercise
Description: the exercise consists of two different modalities: moderate-intensity continuous training (MICT): the main MICT program will be designed to last 30 minutes. The MICT will be designed to involve core muscle training (e.g., march, step touch, lunge, V-step, box step, twist, knee up, scoop, and scissors).~high-intensity interval training (HIIT): The HIIT motions will be a mix of spiderman mountain climbers, standing oblique crunches, squats, froggers, jumping jacks, foot fire, jump squats, and mountain climbers. A total of four sets will be performed with 1-minute rests between sets. Each set comprises eight motions, with each motion lasting 30 seconds and a rest interval of 10 seconds between motions. Participants in the HIIT group will perform the most repetitions possible within 30 seconds.
Study: NCT05716893

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Adaptive Aerobic Training/AT Dosing
Description: o In Phase A (\~32 weeks), AT will consist of supervised walking delivered up to 7 days per week using an adaptive dosing schedule that starts at 90 min/wk and is escalated 30 min/wk every 2 weeks to a maximal dose of 300 mins/wk. In Phase B (\~20 weeks), AT will consist of supervised adaptive AT dosing in patients with a CRF Δ\<3.50 ml O2 .kg-1.min-1 from baseline to \~32 weeks, or unsupervised AT in patients with a CRF Δ\>3.50 ml O2 .kg-1.min-1 from baseline to \~32 weeks. Supervised AT will be monitored using TeleEx.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard (fixed) Aerobic Training/AT dosing
Description: In Phase A (\~32 weeks), AT will consist of supervised walking delivered up to 7 days per week to achieve a cumulative total duration of: 90 min/wk (standard fixed dosing). In Phase B (\~20 weeks), AT will consist of supervised adaptive AT dosing in patients with a CRF Δ\<3.50 ml O2 .kg-1.min-1 from baseline to \~32 weeks, or unsupervised AT in patients with a CRF Δ\>3.50 ml O2 .kg-1.min-1 from baseline to \~32 weeks. Supervised AT will be monitored using TeleEx.
Study: NCT04812002

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PD-1 inhibitor， bevacizumab
Description: Both drugs are given intravenously
Study: NCT06268067

Intervention type: DEVICE
Intervention: PET/CT
Description: F-18 FDG PET/CT studies

Intervention type: DEVICE
Intervention: PET/CT
Description: F-18 FDG PET/CT studies
Study: NCT06584110

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Buddy-Up Dyadic Physical Activity (BUDPA) program
Description: BUDPA program is an overall 16-week training which comprises three phases: the conditioning, consolidating and habituating phases.~i) Conditioning Phase (1st - 4th week) is the preparatory phase to introduce exercise movements in group training.~ii) Consolidating Phase (5th -12th week) is the training phase for group-based exercise. Each exercise training session will be followed by a 20-min debriefing and goal-setting session. Self-practice will be recorded on a simple logbook.~iii) Habituating phase (13th-16th week) aims at supporting the care dyad to integrate the partner exercises into their daily lifestyle. A video call meeting with the care dyad in week 13 and week 15 will be scheduled to offer the support.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Usual care with waiting list
Description: Usual care group will be put on a waiting list to receive the intervention (BUDPA program) after 24-weeks (T2) the second evaluation timepoint.
Study: NCT06020183

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hybrid hyrax
Description: these patents will be treated using Four mini-screws supported hybrid hyrax
Study: NCT04616729

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Triptorelin 3.75 MG Injection
Description: Depot Group (Group A) will receive Triptorelin 3.75mg Depot form for final oocyte maturation.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Transvaginal oocyte retrieval
Description: Patients in both groups will undergo a transvaginal oocyte retrieval after ovarian stimulation.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Transvaginal oocyte retrieval
Description: Patients in both groups will undergo a transvaginal oocyte retrieval after ovarian stimulation.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Triptorelin Injection
Description: Daily Group (Group B) will receive Triptorelin 0.2mg Daily form for final oocyte maturation.
Study: NCT05133973

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: FiberSense CGM
Description: FiberSense system, a novel CGM system, based on a fiber-optical sensor placed through the dermis of the patient.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: FiberSense CGM
Description: FiberSense system, a novel CGM system, based on a fiber-optical sensor placed through the dermis of the patient.
Study: NCT05008939

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sevoflurane
Description: Patients receive 1% sevoflurane and 30% oxygen for 1 hour.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients received 30% oxygen for 1 hour.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Patients received 30% oxygen for 1 hour.
Study: NCT05901064

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Axillary clearance
Description: Evaluating the use of Harmonic Focus in axillary clearance due to metastasis of breast cancer in axilla

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Axillary clearance
Description: Evaluating the use of Harmonic Focus in axillary clearance due to metastasis of breast cancer in axilla
Study: NCT04614168

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Stepped hyperinsulinaemic-hypoglycaemic clamp study
Description: Participants will commence on a primed insulin infusion at a constant rate of 60mU/m2/min along with a variable rate 20% glucose infusion. Participants will have their blood glucose monitored every 5 minutes. The glucose infusion will be altered to achieve the desired blood glucose plateaus of: 5mmol/l, 3mmol/l and 2.5mmol/l. Each plateau will be held for 40 minutes. During each plateau blood samples will be taken on three occasions for: glucagon, cortisol, adrenaline, noradrenaline, D2 glucose and D5 glycerol. On two occasions during each plateau participants will complete the Edinburgh hypoglycaemia scale and the following cognitive tests: trail making test, digit span test, digit symbol substitution test and four choice reaction time test. At the end of the clamp study the insulin infusion will be discontinued and the blood glucose will be allowed to rise to the normal range. Participants will consume lunch before leaving the clinical research facility.
Study: NCT06315426

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT05082961

Intervention type: OTHER
Group type: OTHER
Intervention: Collection of blood samples
Description: Samples to evaluate the circulating CD8+ T cell count.

Intervention type: OTHER
Group type: OTHER
Intervention: Collection of blood samples
Description: Samples to evaluate the circulating CD8+ T cell count.
Study: NCT06211322

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Urika, a self-management application for patients with gout
Description: The self-management software application (Urika) will include information videos on gout and treatment, reminders of daily medication and blood tests, a built-in algorithm for medical dosage escalation, visualization and log of serum urate levels, motivational gamification, asynchronous chat function patient-health professionals, and a platform for remote monitoring by health professionals.
Study: NCT06260397

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: serratus anterior plane block
Description: using ultrasound, 30 ml of bupivacaine 0.25% will be injected in the plane between the latissimus dorsi and serratus muscles

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: costotransverse block
Description: using ultrasound, 30 ml of bupivacaine 0.25% will be injected in the costotransverse plane of fourth rib

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: patient controlled analgesia
Description: PCA pump in the form of 20 mg nalbuphine HCL in 100 ml 0.9% normal saline with basal rate of infusion 5ml/hr. with self-administration bolus of 0.5ml with 15 min lock-out time.
Study: NCT06520124

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Essilor® Stellest® spectacle lens
Description: Spectacle lens with highly aspherical lenslets.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Essilor® Stellest® spectacle lens
Description: Spectacle lens with highly aspherical lenslets.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Single-vision spectacle lens
Description: Standard single-vision distance spectacle lens.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Single-vision spectacle lens
Description: Standard single-vision distance spectacle lens.
Study: NCT04092010

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Problem-solving education (PSE)
Description: PSE will be offered to mothers with low baseline depressive symptoms (the first, preventive step of the SCI). PSE participants will have their symptoms assessed at each session and will convert to Engagement Sessions if they meet pre-specified 'step up' criteria.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Engagement sessions
Description: Engagement sessions will be offered to mothers with greater depressive symptoms to link them to formal mental health services (the second, referral step of the SCI)

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual care
Description: Normal services provided children and their mothers in Head Start